Clinical Trial Update: UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial exploring UC-MSCs for severe and critical COVID-19 patients; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• UC-MSCs (umbilical cord-derived mesenchymal stem cells)

Snippet

Sponsor: Shanghai East Hospital | Conditions: Mesenchymal Stem Cell, COVID-19 Pneumonia | Phase 3 | Status: UNKNOWN